Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | MRGPRX1 | Q96LB2 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | UGCG | Q16739 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7792150 | 0.89 | KMT2A (0.44) | KMT2AMEN1POLBHSD17B10MAPT | |
| SCHEMBL7797946 | 0.86 | KMT2A (0.43) | KMT2AMEN1POLBHSD17B10LMNA | |
| SCHEMBL7799951 | 0.86 | MEN1 (0.49) | KMT2AMEN1POLBMRGPRX1LMNA | |
| SCHEMBL7801338 | 0.86 | KMT2A (0.45) | KMT2AMEN1POLBMAPTNR1I2 | |
| SCHEMBL7799980 | 0.86 | HSD17B10 (0.43) | KMT2AMEN1HSD17B10LMNAMAPT | |
| SCHEMBL7801319 | 0.86 | KMT2A (0.43) | KMT2AMEN1POLBLMNAMAPT | |
| SCHEMBL7799922 | 0.85 | KMT2A (0.43) | KMT2AMEN1POLBMAPTNR1I2 | |
| SCHEMBL8068248 | 0.84 | MEN1 (0.43) | KMT2AMEN1MAPTNR1I2UGCG | |
| SCHEMBL7797937 | 0.83 | KMT2A (0.44) | KMT2AMEN1POLBMAPTNR1I2 | |
| SCHEMBL7802459 | 0.83 | KMT2A (0.43) | KMT2AMEN1POLBMAPTNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010025045-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | SMITHKLINE BEECHAM P.L.C. | 2001-09-27 | — | — | US | disclosed |
| EP-1025087-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999021836-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025045-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | INA, GRIN2C, GRIN2A | KMT2A 445/4885MEN1 3408/4885POLB 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.